Status: Recruiting
Efficacy and Safety of Dose Redution of Radotinib as a First Line Treament in Ph+ CML
The goal of this observational study is to learn about the efficacy and safety profile when Radotinib dose redution is performed in Ph+ CML subjects. The main efficacy is checked by MMR rate by 12 months from IP treatment.
Participants needed: 168
Trial details
Age: 19+Biological sex: AllType: ObservationalSponsor: Il-Yang Pharm. Co., Ltd.Updated: Oct 30, 2024Locations: 2
Eligibility criteria
Male or female patients aged 19 years old or older [+16]
Patients with Philadelphia chromosome negative [+29]